#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    HER2 mutant non-small cell lung cancer B-cell small lymphocytic lymphoma recurrent Pleural mesothelioma malignant Insulinoma Glomerulonephritis acute Phaeochromocytoma Breast cancer metastatic Small cell lung cancer limited stage Alternating hemiplegia of childhood Conjunctivitis allergic Idiopathic pulmonary fibrosis Depression Acute myeloid leukaemia Glioblastoma multiforme Spina bifida More trials…

    Learn about Rare Diseases

    Piriformis syndrome Anaplastic thyroid cancer – Treatment Propionic acidaemia – Basic Information Hypereosinophilic syndrome – Treatment Proteus syndrome – Basic Information Systemic mastocytosis – Life with Disease Stevens-Johnson syndrome – Treatment Nodal marginal zone B-cell lymphoma Chondrosarcoma – Treatment Cystic fibrosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vib1116 Mitoxantrone Miransertib Vonafexor Narsoplimab Aticaprant Elamipretide Trihydrochloride Trabectedin Oxybutynin Crovalimab Micronised Spironolactone Urapidil Cefotaxime Sodium Ucp2 Masofaniten ROPINIROLE GSKVX000000039711 Disodium Folinate Efpegerglucagon Cpft Trifluoroacetate More therapies…

    Learn about Your Condition

    Thrombosis Fibrosarcoma Skin papilloma Chondrosarcoma metastatic Osteoporosis Gaucher's disease type III K-ras gene mutation Rhinitis allergic Amyloidosis Pemphigus Endocarditis Brain injury Intermittent claudication Hepatic fibrosis Coma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multiple sclerosis

  • Study on the Effects of Semaglutide and Dulaglutide in Adults with Multiple Sclerosis Aged 18-60 with High Disease Activity

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Dulaglutide
    • Semaglutide
    Slovakia

  • A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    France Germany Italy Poland Spain

  • Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +12

  • Study on Masitinib for Treating Primary or Secondary Progressive Multiple Sclerosis in Patients Without Relapse

    Not recruiting

    3 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Masitinib
    France Greece Poland Spain

  • Study on the Effects of Cladribine on Brain Cells in Patients with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Cladribine
    Finland

  • Study on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS
    Spain
Previous Page
1 … 3 4 5 6 7 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!